Pegfilgrastim/Neulasta
® is a pegylated form of filgrastim. Pegylated means that polyethylene glycol, a dispensing agent, has been added to the drug. Filgrastim is a synthetic human granulocyte colony-stimulating factor (G-C SF). Pegfilgrastim is produced by recombinant DNA technology using E. coli bacteria.
Filgrastim/Neupogen
® and Pegfilgrastim/Neulasta ® are C SFs that act on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Filgrastim-sndz/Zarxio
® is biosimilar to Neupogen ® (filgrastim).
Filgrastim-aafi/ Nivestym™ is biosimilar to Neupogen ® (filgrastim).
Pegfilgrastim-jmdb/Fulphila™ is biosimilar to Neulasta ® (pegfilgrastim).
Tbo-filgrastim/Granix
® is a non-glycosylated recombinant methionyl human granulocyte colony-stimulating growth factor (G-C SF) manufactured by recombinant DNA technology using the bacterium E. coli Sargramostim/Leukine ® is a synthetic granulocyte-macrophage colony-stimulating factor (GM-C SF) produced by recombinant DNA technology in S. cerevisiae yeast. Granulocyte Macrophage C olony Stimulating Factor (GM-C SF) is an antineutropenic, hematopoietic growth factor, which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells.
Indications
Filgrastim (Neupogen   ®   ) , Filgrastim-sndz (Zarxio ® ), and Filgrastim-aafi (Nivestym™) are approved for the following uses:
• Patients with C ancer Receiving Myelosuppressive C hemotherapy: Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever.
•
Patients with Acute Myeloid Leukemia Receiving Induction or C onsolidation C hemotherapy: Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML).
Related Medicare Advantage Policy Guidelines Tbo-filgrastim (Granix ® ) is approved for the following uses:
• Patients with C ancer Receiving Myelosuppressive C hemotherapy: To reduce the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
Sargramostim (Leukine ® ) is approved for the following uses: • Acute Myeloid Leukemia Following Induction C hemotherapy: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). Limitations C olony stimulating factors are not covered when:
Administered by a caregiver
Dosing Information
Dose and frequency should be in accordance with the FDA label or recognized compendia (for off-label uses). When services are performed in excess of established parameters, they may be subject to review for medical necessity.
Documentation Requirements
• The patient's medical record must document the medical necessity of services performed for each date of service submitted on a claim, and documentation must be available upon request. 
APPLIC ABLE C ODES
The following list(s) of codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this guideline does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply. 
DEFINITIONS

Biosimilar:
The biological product is approved based on data demonstrating that it is highly similar to an FDAapproved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product.
Off-Label Drug Use: An off-label/unlabeled use of a drug is defined as a use for a non-FDA approved indication, that is, one that is not listed on the drug's official label/prescribing information. An indication is defined as a diagnosis, illness, injury, syndrome, condition, or other clinical parameter for which a drug may be given. Off-label use is further defined as giving the drug in a way that deviates significantly from the labeled prescribing information for a particular indication. This includes but is not necessarily limited to, dosage, route of administration, duration and frequency of administration, and population to whom the drug would be administered. Drugs used for indications other than those in the approved labeling may be covered if it is determined that the use is medically accepted, taking into consideration the major drug compendia, authoritative medical literatures and/or accepted standards of medical practice. Determinations as to whether medication is reasonable and necessary for an individual patient are made on appeal on the same basis as all other such determinations (i.e., with support from the peer-reviewed literature, with the advice of medical consultants, with reference to accepted standards of medical practice, and in consideration of the medical circumstance of the individual case).
Primary Prophylaxis: Refers to administration of C SF during the first cycle of chemotherapy.
Secondary Prophylaxis:
Refers to administration of C SF during subsequent cycles of chemotherapy.
Severe Neutropenia: Generally defined as an absolute neutrophil count of less than 500 cells per ml. Benefit coverage for health services is determined by the member specific benefit plan document* and applicable laws that may require coverage for a specific service. The member specific benefit plan document identifies which services are covered, which are excluded, and which are subject to limitations. In the event of a conflict, the member specific benefit plan document supersedes the Medicare Advantage Policy Guidelines.
PURPOSE
Medicare Advantage Policy Guidelines are developed as needed, are regularly reviewed and updated, and are subject to change. They represent a portion of the resources used to support UnitedHealthcare coverage decision making. UnitedHealthcare may modify these Policy Guidelines at any time by publishing a new version of the policy on this website. Medicare source materials used to develop these guidelines include, but are not limited to, C MS National C overage Determinations (NC Ds), Local C overage Determinations (LC Ds), Medicare Benefit Policy Manual, Medicare C laims Processing Manual, Medicare Program Integrity Manual, Medicare Managed C are Manual, etc. The information presented in the Medicare Advantage Policy Guidelines is believed to be accurate and current as of the date of publication, and is provided on an "AS IS" basis. Where there is a conflict between this document and Medicare source materials, the Medicare source materials will apply. Medicare Advantage Policy Guidelines are the property of UnitedHealthcare. Unauthorized copying, use and distribution of this information are strictly prohibited.
*For more information on a specific member's benefit coverage, please call the customer service number on the back of the member ID card or refer to the Administrative Guide.
